10.1.1 The increase in outsourcing of sterile injectable drugs is occurring for several reasons. The greater complexity of formulations and drug–device combination products is limiting the number of pharma companies willing to enter into sterile injectable drug manufacturing.[176] Small and emerging biotechs tend to outsource because they lack the resources and knowledge to implement complex aseptic production processes and all of the associated supporting activities, and such companies are showing increased interest in retaining new products beyond proof of concept, necessitating longer-term outsourcing relationships. Many of these smaller companies also look to CDMOs for assistance with formulation and analytical development, quality control, and regulatory support services.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
10.2.1 The overall sterile injectables market is led by North America and is followed closely by Europe in terms of revenue, but the greatest demand growth for these products is occurring in the Asia–Pacific region.[188] Similarly, North America is projected to continue to lead the generic sterile injectables market in terms of revenue (>25%) for at least the next several years, but Asia–Pacific will experience the highest growth rate.[189][190] The fill/finish manufacturing market, on the other hand, is led by Europe and closely followed by North America.[191] In this market, the Asia–Pacific region is, however, also growing at the fastest rate.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
10.3.1 The CDMO landscape for bulk sterile injectables manufacturing is fragmented and includes both small firms focused only on sterile fill/finish and large, international, integrated CDMOs that offer support for the development and production of small- and large-molecule drugs in multiple dosage forms. Some large biopharmaceutical companies also offer outsourcing services through CDMO businesses.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
10.4.1 The astounding adoption of GLP-1 agonist drugs (commonly referred to as GLP-1 drugs) has had a significant impact on the sterile injectables market. The two largest manufacturers, Lilly and Novo Nordisk, were the drivers of significant market changes as they established their own supply chains for GLP-1 vials and prefilled syringes. Novo Nordisk bought Catalent and converted most of Catalent’s capacity to GLP-1 drug substance (DS) and drug product (DP) production. Lilly then pulled most of their DP work from Catalent and reestablished their supply chain with a series of other fill/finish suppliers. Demand for vaccines has fallen, mostly in the U.S., as consumer vaccine hesitancy continues. This reluctance relieves sterile capacity contraints somewhat, but not enough to mitigate an overall sterile shortage. The remaining sterile customers are now scrambling for “leftover” capacity and often find themselves needing multiple suppliers to fill their requirements as slots are available.
10.4.2 As one might expect, the capacity crunch has led to longer lead times for smaller players and increased prices. One subject matter expert (SME) from a major DS/DP vendor told us that fill/finish prices have been increasing by >10% annually since the GLP-1s came onto the market. This means that sterile pricing is increasing at a far faster rate than any other aspect of the CDMO market that we track.
10.4.3 Companies are expanding their sterile capacity, as we noted in Section X, so the manufacturing capacity will eventually catch up with current demand. Additional drugs, however, such as GLP-1 biosimilars and next-generation GLP-1 drugs with reduced side effects or longer dosing schedules, have the potential to keep the supply chain constrained in the short term.
10.4.5 When assessing market capacity constraints, it is important to recognize that vials and syringes are usually filled on the same production lines. As a result, any company with these capabilities can supply GLP-1 drugs, which in turn reduces manufacturing availability for smaller customers. Because GLP-1 drugs are typically not lyophilized, however, this aspect of the market has not been impacted by GLP-1 demand. Lyophilization capacity, however, has traditionally been constrained for several years due to the difficulty and expense of upgrading equipment and this trend will continue in the short term.
10.4.6 Until capacity catches up with demand, sterile prices have increased and are continuing to do so. In the summer of 2025, we found that clinical sterile prices have increased 20% to 30% over 2023. Additionally, we learned that smaller developers are often charged price premiums that can be 20% to 30% on top of the values listed in our pricing tables for services and consumables. Commercial pricing, however, hasn’t increased quite as fast, probably because these contracts are often longer term, and so the CDMOs haven’t yet renegotiated pricing for existing customers.
10.4.7 The GLP-1 demand, of course, not only increases the prices quoted for the smaller clients, but also extends timelines. Catalent’s acquisition by Novo Holdings removes a significant amount of capacity from the market, and capacity constraints are likely to persist until other CDMOs expand their operations.
10.4.8 One industry insider commented that biologics DS CDMOs have not significantly expanded their standalone fill/finish offerings, despite these capacity constraints. We see this trend in our own research, and the reader will note the relatively short list of DP capacity expansions by DS firms in Table 18.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
10.5.1 With the sterile injectable drug market growing markedly even before COVID-19, CDMOs offering services related to the development and manufacture of sterile drug products have been investing to expand their facilities and capabilities. A summary of recent capacity expansions (Table 18) and M&A activity (Table 19) are presented below.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.